PTC Therapeutics Inc’s recently made public that its CHIEF BUSINESS OFFICER Pauwels Eric unloaded Company’s shares for reported $0.38 million on Mar 17 ’25. In the deal valued at $56.80 per share,6,762 shares were sold. As a result of this transaction, Pauwels Eric now holds 72,640 shares worth roughly $4.15 million.
Then, Pauwels Eric sold 4,458 shares, generating $246,037 in total proceeds. Upon selling the shares at $55.19, the CHIEF BUSINESS OFFICER now owns 79,402 shares.
Before that, Okey Stephanie sold 5,000 shares. PTC Therapeutics Inc shares valued at $270,000 were divested by the Director at a price of $54.00 per share. As a result of the transaction, Okey Stephanie now holds 8,867 shares, worth roughly $0.51 million.
BofA Securities upgraded its PTC Therapeutics Inc [PTCT] rating to a Neutral from a an Underperform in a research note published on March 11, 2025; the price target was increased to $55 from $41. A number of analysts have revised their coverage, including Scotiabank’s analysts, who began to cover the stock in early March with a ‘”a Sector perform”‘ rating. Morgan Stanley also remained covering PTCT and has increased its forecast on December 13, 2024 with a “an Overweight” recommendation from previously “an Equal-weight” rating. RBC Capital Mkts revised its rating on December 03, 2024. It rated PTCT as “an Outperform” which previously was an “a Sector perform”.
Price Performance Review of PTCT
On Friday, PTC Therapeutics Inc [NASDAQ:PTCT] saw its stock jump 0.90% to $57.14. Over the last five days, the stock has gained 4.84%. PTC Therapeutics Inc shares have risen nearly 26.58% since the year began. Nevertheless, the stocks have risen 87.78% over the past one year. While a 52-week high of $58.38 was reached on 03/17/25, a 52-week low of $24.00 was recorded on 01/14/25. SMA at 50 days reached $49.65, while 200 days put it at $40.97.
Levels Of Support And Resistance For PTCT Stock
The 24-hour chart illustrates a support level at 56.13, which if violated will result in even more drops to 55.13. On the upside, there is a resistance level at 57.74. A further resistance level may holdings at 58.35. The Relative Strength Index (RSI) on the 14-day chart is 65.59, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 2.74, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 14.71%. Stochastics %K at 84.86% indicates the stock is a selling.
How much short interest is there in PTC Therapeutics Inc?
A steep rise in short interest was recorded in PTC Therapeutics Inc stocks on 2025-02-28, dropping by -0.37 million shares to a total of 3.79 million shares. Yahoo Finance data shows the prior-month short interest on 2025-01-31 was 4.16 million shares. There was a decline of -9.82%, which implies that there is a negative sentiment for the stock.
